Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy? - Cancer Currents Blog

National Cancer Institute sent this bulletin at 10/31/2022 11:06 AM EDT

Having trouble viewing this email? View it as a Web page.

Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?
10/27/2022
	Two research teams have developed a treatment approach that could potentially enable KRAS-targeted drugs—and perhaps other targeted cancer drugs—to flag cancer cells for the immune system. In lab studies, the teams paired these targeted drugs with experimental antibody drugs that helped the immune system mount an attack.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.